How to Cite
References
Wei-Ting L, Chih-Cheng L, Jian-Jhong W, Chien-Ming C. Effect of polymyxin B hemoperfusion on the outcome of patients with sepsis and septic shock. J Infect 2020;80(3):350-371.DOI: https://doi.org/10.1016/j.jinf.2019.11.013
Jörres, A. Blood purification in sepsis. Crit Care. 2018;357. DOI: https://doi.org/10.1186/s13054-018-2286-4
De Rosa S, Villa G, Ronco C. The golden hour of polymyxin B hemoperfusion in en-dotoxic shock: The basis for sequential extracorporeal therapy in sepsis. Artif Organs. 2020;44(2):184-186. DOI: https://doi.org/10.1111/aor.13550
Srisawat N, Tungsanga S, Lumlertgul N, Komaenthammasophon C, Peerapornratana S,Thamrongsat N, et al. The effect of polymyxin B hemoperfusion on modulation of humanleukocyte antigen DR in severe sepsis patients. Crit Care. 2018;279. DOI: https://doi.org/10.1186/s13054-018-2077-y
Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B he-moperfusion in endotoxemic septic shock patients without extreme endotoxemia: a posthoc analysis of the EUPHRATES trial. Intensive Care Med. 2018; 44(12):2205-2212. DOI:https://doi.org/10.1007/s00134-018-5463-7
Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza, N, Donati A, et al. Early use ofpolymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized contro-lled trial. JAMA. 2009;301(23):2445-2452. DOI: https://doi.org/10.1001/jama.2009.856
Payen DM, Guilhot J, Launey Y, et al. Early use of polymyxin B hemoperfusion in patientswith septic shock due to peritonitis: a multicenter randomized control trial. Intensive CareMed. 2015;41(6):975-984. DOI: https://doi.org/10.1007/s00134-015-3751-z
Terayama T, Yamakawa K, Umemura Y, Aihara M, Fujimi S. Polymyxin B Hemoperfu-sion for Sepsis and Septic Shock: A Systematic Review and Meta-Analysis. Surg Infect.2017;18(3):225-233. DOI: https://doi.org/10.1089/sur.2016.168
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.